Steven Cohen Bellus Health Inc. Transaction History

Point72 Asset Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$5.26 - $8.3 $653,702 - $1.03 Million	-124,278 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.7 - $6.64 $12.2 Million - $30 Million	-4,516,370 Reduced 97.32%	124,278 $763,000
Q2 2021 Aug 16, 2021	SELL	$3.11 - $4.61 $3.61 Million - $5.34 Million	-1,159,352 Reduced 19.99%	4,640,648 $14.4 Million
Q1 2021 May 17, 2021	SELL	$3.03 - $4.58 $1.27 Million - $1.92 Million	-420,058 Reduced 6.75%	5,800,000 $22.3 Million
Q4 2020 Feb 16, 2021	BUY	$2.27 - $3.3 $14.1 Million - $20.5 Million	6,220,058 New	6,220,058 $19 Million

Q3 2020 Nov 16, 2020	SELL	$2.14 - $12.02 $734,550 - $4.13 Million	-343,248 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$8.88 - $11.15 $3.05 Million - $3.83 Million	343,248 New	343,248 $3.53 Million
Q4 2019 Feb 14, 2020	SELL	$5.76 - $7.6 $232,093 - $306,234	-40,294 Closed	0 $0
Q3 2019 Nov 15, 2019	BUY	$6.24 - $8.84 $251,434 - $356,198	40,294 New	40,294 $257,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.